哪里想瘦打哪里！FDA批准Kythera注射药物纳斯达克在即

你才双下巴，你家中都双下巴！所谓爱美之心人皆有之。如果说赘肉是每一个希望拥有完美体格的“妹纸”或“汉纸”的敌手，那么一个喜感十足的双下巴称得上是这些人的究竟仇敌了。每一分钟，世界各地都有人为自己的一张大饼脸而沮丧烦恼，虽然拥有一个肉感十足的双下巴捏跟着是挺有肉感的，但是还是有很多人的体格使其很难承受一个双下巴之重。您可千万别今晚，这甚至已经催生出一个庞大的消费市场。根据美国黏膜外科理事会的报告研究显示，68%的加拿大人对自己的双下巴声称了“厌倦”之情。而有鉴于此，在在KytheraCorporation向FDA提交了其专为歼灭双下巴的护肤注射的单本品ATX-101。这种本品完成了许多“胖纸”梦寐以求的系统，哪里想瘦打哪里，称得上是不间断肥胖。免得以为这种近乎天真的本品只是一个今晚话，在FDA的下属的黏膜和眼科本品专员会的无记名表决中会，专家可是以17：0的超高选票原则上拥护其上市。或许是因为这些专家中会也有很多屡受双下巴之苦吧。FDA也将计划案于去年的5月末13日以前对其采取行动最后尽快。如果一切顺利的话，KytheraCorporation计划案于去年月初将该厂家上市，量化人士预计这一本品的年销售额将超过3亿美元之多。随着护肤本品消费市场的愈加增大，KytheraCorporation称得上是下了一步好棋。Corporation于去年以8400万美元的单价从其前合作标下主导权会收回了这种本品的全部基本权利。而KytheraCorporation也希望用意为后所在护肤本品消费市场中会入城拔寨。就在上个月末，KytheraCorporation和ActelionCorporation达成意义2700万美元的合作协议书，共同合作开发一种失败过的促病变本品，而这种本品被确信有可能合作开发出一种治疗脱发的本品。详述直译报道：Kythera ($KYTH) won the unanimous support of an FDA advisory panel for its fat-busting injection, rolling toward approval with a first-of-its-kind treatment.The agency's independent Dermatologic and Ophthalmic Drugs Advisory Committee voted 17-0 that the drug's benefits outweighed its risks for patients looking to reduce submental fat, or double chin. The FDA is not required to follow its panels' votes, though it most commonly does, and the agency has promised to make a final decision on the injection by May 13. If all goes according to plan, Kythera plans to launch the drug, ATX-101, in the second half of this year.The biotech's shares he more than tripled since it pulled off a $73 million IPO in 2012, rising steadily as investors bet ATX-101 can carve out a space on the aesthetic market and potentially lure a Big Pharma acquirer. Kythera is pitching the injection as a much-needed nonsurgical option for double chin reduction, citing an American Society for Dermatologic Surgery survey that estimates 68% of Americans are "bothered" by submental fat.Kythera regained full rights to ATX-101's potential last year, orchestrating an $84 million deal to buy out ex-partner Bayer. And the drug, a synthetic version of the fat-blasting deoxycholic acid, could bring in more than $300 million a year once approved, Leerink yst Seamus Fernandez has said."This milestone demonstrates our commitment to developing first-in-class aesthetic products through a focus on scientific rigor and innovation," Kythera CEO Keith Leonard said in a statement. "At Kythera, we remain focused on investing in novel treatments that will allow aesthetic physicians to better meet the needs of their patients."Kythera is also focused on raising some cash now that it has a likely approval ahead. The biotech filed for a $125 million offering as soon as the market closed on Monday. Its share price was down several points at the end of the day.Beyond its top prospect, Kythera is working to build out a pipeline of aesthetic medicines. Last month, the California biotech signed a $27 million deal with Actelion ($ATLN) to get its hands on a once-failed anti-inflammatory medicine that could he a future as a treatment for hair loss.